The years before the prescription
Nathan Chadwick · · 10 min read
Listen
TLDRRead the short version
- The impairment starts years before the letter. A diagnosis is permission to begin a medicine that already existed.
- In June 2026 NHS England counted up to 959,662 open referrals that may be for an ADHD assessment. Adult waits of eight years, and in some areas ten to fifteen, are already in the NHS's own review.
- NICE's first-line treatments are established medicines. A six-week trial with a prescriber checking pulse and blood pressure is the safety step. A decade on a list is a decade of untreated risk.
- In the same person, medicated periods come with lower rates of conviction, and in men with fewer serious crashes. The trouble often happens in the years before the letter.
- A named prescriber stays in the picture. There is no dose here and no source. The argument is that permission should arrive while a life can still be lived.
The problem started in the years when getting out of bed, holding a thought, leaving the house, and staying out of a mess were all more expensive than they should have been.
I have written about being flat from the age of eleven, and about the prescription that did arrive: listened to, sympathised with, given an antidepressant, and sent on, while nobody took blood for twenty years. I have written about the house, and about RuneScape being the place the rules were readable when outside was too expensive. What I want to say here is narrower. A lot of that could have been smaller. The medicines that make this kind of brain more able to run a day have existed for decades. The system withholds them until a specialist agrees the struggle has the right name. By then the struggle has already had a life.
Permission#
A diagnosis describes something that was already happening. In practice it is also a key. The medicine sits behind it. So do school support, a workplace adjustment, and a GP willing to continue a prescription. The impairment does not wait for the key. The person does.
Help, if the word means anything, is what lets someone function in the years that decide a life. School. A first job. Learning to drive. Learning to get through an evening without drinking the noise down. Learning to leave a gap between a feeling and the sentence, so the relationship, the shift, and the bill survive it. A letter that arrives after those years records what was missed.
ADHD is the clearest version, because the wait is now measured in public and the medicine is unusually well studied. It is the same machine anywhere the useful treatment is controlled, specialist, or unfamiliar. The familiar prescription gets the short door. The specific one gets the long one.
The queue England has built#
In June 2026 NHS England counted up to 959,662 open referrals that may be for an ADHD assessment. The same release estimates that about 2,478,000 people in England have ADHD, including people with no diagnosis at all. The count is experimental, and it says "may be", because the datasets are not a clean waiting-room register. The size of it is still the point.
The independent ADHD Taskforce, asked by NHS England to look at the service, does not soften the wait. Part 1 says adult waits have risen to eight years and more, and children's waits to four years and more. The easy-read summary says that in some areas the wait has grown to ten to fifteen years. It names what a long wait costs, in the plainest language the NHS publishes: mental health getting worse, suicide, and trouble with the law.
The same review says England still under-treats the people who already meet strict criteria. Fewer than a third of those children have contact with any mental health service. Only 15 to 25% of the adults and children get medication. Demand is rising partly because adults who were missed as children are finally asking, and partly because the rules changed. For a long time the manuals made autism and ADHD a choice. You could be recorded as one. Plenty of people were both, and the half that did not fit the form went untreated. I live on that overlap. The impairment never respected the form.
There is a second lock after the letter. Shared care, where a specialist starts a medicine and a GP continues it, has been falling apart. Part 2 of the Taskforce report records people who did well on medication and then could not get it from their own practice. Right to Choose can move an assessment. It does not guarantee the prescription survives contact with the GP. If you can pay, you rent continuity. If you cannot, you stop a medicine that was already working. I have been through the money version of that with a different treatment. Finding the answer and being allowed to keep the answer are two different prices.
Already in the guideline#
NICE's first-line medicines for adults with ADHD are lisdexamfetamine and methylphenidate. The guidance is a six-week trial at a proper dose, then a switch if that one has not helped enough. That trial is the safety step. A prescriber. A check on pulse and blood pressure. A review of sleep, appetite, and whether ordinary life got more possible.
These are established medicines. Methylphenidate has been used for this pattern of impairment for decades. The Taskforce's summary of the outcome data is blunt. For people who meet full criteria, medication reduces symptoms in about 70 to 89%. The Taskforce also notes that stimulant effect sizes come out larger than those reported for statins and blood pressure tablets. Registry studies, comparing the same person on medication and off it, find lower rates of criminal conviction, less long-term unemployment, fewer suicide attempts, and fewer substance-related problems in the medicated periods. In men, medication is associated with fewer serious transport accidents. A registry comparison is the strongest design you can run on a country's records. The treated stretches are quieter.
Part 2 puts the economic cost of not treating ADHD at around £17 billion, drawing on a sibling-comparison study of the burden. I do not need the billion to make the point. A person who can work, drive, and stay in a life is cheaper than a person who cannot. The science of "this can help" was settled enough to write into a guideline. Permission was the part still missing.
Out of trouble#
Trouble gets used as if it means a person is bad. The records describe timing.
Most people with this wiring never see a courtroom. The damage is often smaller, and it still eats a decade. The task does not start. The job goes. The bill becomes a debt because it could not be held in mind. The evening is too loud and too fast, so the drink does the quieting, and then the drink is the problem everyone treats. The sentence leaves with no gap, and the relationship takes it. The house becomes the only safe room, because outside has too many unwritten rules and the body already learned that being seen is expensive. I have lived in that version. The computer kept me steady. It also kept the years small. Functional, for me, means a day that can start, a life that can be left and returned to, and a nervous system that is not doing the deciding.
For some people the trouble does become a record. The Taskforce says ADHD is over-represented in the criminal justice system, and it cites figures around a quarter of people in prison. A 2024 analysis limited to unselected samples put the figure nearer one in twelve, and argued that the higher estimates mixed in selected groups. Either figure sits above the rate outside. Contact starts younger and comes back more often. A conviction then blocks the job, the flat, and the next ten years.
What changes in the data is the timing. In the Swedish registry study, among 25,656 people with ADHD, the rate of criminal convictions in the same person was about a third lower for men and about two fifths lower for women during periods on medication. A separate Swedish study found a 58% lower risk of a serious transport accident in men during treatment, and no clear reduction in women. The harm clusters in the untreated stretches.
An eight-year list is eight years in which the crash, the drink, the lost work, and the police can happen, while a medicine that reduces those risks sits in a guideline. The Taskforce says uncomplicated ADHD is easier to support at the start, in childhood, than it is once school has been abandoned and illness and substances have arrived. The service does the later version. It meets people after the consequences have a file, and then treats the file as the reason to be slow.
A prescriber is the safety#
Stimulants are controlled drugs because they can be diverted, and because they are not harmless. Sleep, appetite, pulse, blood pressure, and anxiety can all move the wrong way. Someone else's medicine in someone else's hands is a real harm. A named prescriber and a review exist for that reason.
I am not a doctor. There is no dose on this page and no source. If a medicine you are already prescribed is working, this is not a reason to stop it, and stopping a psychiatric medicine suddenly is its own risk. That conversation belongs with the person who prescribed it.
The lock is in the wrong place. A GP, or a nurse with a specialist they can actually reach, can take a history, see that the impairment has run for years and across more than one part of life, check the physical risks, and start the six-week trial NICE already describes. That is weeks. The Taskforce has asked for ADHD to be handled as a long-term condition, the way depression and diabetes are, with generalists doing the ordinary prescribing and specialists kept for what is actually complicated. The easy-read summary says the quieter version of the same thing: if someone is struggling, help them for the need in front of you, and do not hold the help until a diagnosis exists.
The familiar prescription is the one the system can start today. An antidepressant in a ten-minute appointment is sometimes exactly right. It can also become the whole plan, repeated for years, while the impairment underneath never gets a trial of the medicine with the better evidence for this pattern. I lost a long time to that plan. The controlled, specific medicine is the one with the decade attached.
Private assessment sells the key to people who can pay. The Taskforce is plain that this two-tier access shows up afterwards in education, work, health, and the justice system. A market in permission is a queue with a card machine.
Social media is a poor assessment. Some clinics are poor assessments too, and the Taskforce says that mistrust is already costing people their shared care. Both of those are arguments for a decent history and a review. England's own figures still describe under-treatment of people who already meet the criteria.
The years stay spent#
I know what a day costs when starting is expensive. I run mine as a short script, because a blank afternoon is an open search and the search can eat it. Medicine is one tool that can make the first step cheap enough to happen. A routine, a person who is on your side, and a school or a job that does not punish the wiring all matter. They land better when the brain can meet them.
A known medicine, started before someone had to fail for long enough to be believed, would have been enough. Function is the point. A day that starts. Work that stays. A mood with one less untreated impairment underneath it. Treat the cause while the person can still work, still cope, and still stay clear of the debt, the bottle, and the police.
If you are in that wait, ask the GP what support exists before the letter, and in England ask about Right to Choose. Take a written account of how long this has gone on, at school and at work and at home. If a medicine has already helped and shared care is refused, that refusal is something to push back on with the specialist and the practice.
If you are in danger now: Samaritans on 116 123, any time, free. NHS 111 and the mental health option. CALM on 0800 58 58 58. If you are in immediate danger, 999.
The help was already invented. The years were what we spent.
References#
- NHS England Digital, ADHD Management Information, August 2026
- NHS England, independent ADHD Taskforce, Part 1
- NHS England, independent ADHD Taskforce, Part 2
- Easy-read summary of the ADHD Taskforce report
- NICE NG87, ADHD diagnosis and management
- Cortese et al., comparative efficacy of ADHD medications (Lancet Psychiatry, 2018)
- Lichtenstein et al., ADHD medication and criminality (NEJM, 2012)
- Chang et al., serious transport accidents and ADHD medication (JAMA Psychiatry, 2014)
- Quinn et al., ADHD medication and substance-related problems (American Journal of Psychiatry, 2017)
- Li et al., ADHD medication and long-term unemployment (JAMA Network Open, 2022)
- Chang et al., ADHD medication and suicide attempts (Biological Psychiatry, 2020)
- Fazel et al., ADHD in adult prisoners, unselected samples (Criminal Behaviour and Mental Health, 2024)
- Young et al., ADHD prevalence in incarcerated populations (Psychological Medicine, 2015)
- Daley et al., economic burden of adult ADHD (European Psychiatry, 2019)
- Samaritans
- CALM